Published in:
Open Access 01-12-2020 | Checkpoint Inhibitors | Original Article – Cancer Research
Patient expectations are better for immunotherapy than traditional chemotherapy for cancer
Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2020
Login to get accessAbstract
Purpose
The main aim of the study was to explore the expectations and knowledge of advanced-stage cancer patients about immunotherapy.
Methods
This mixed methods study included 53 cancer patients on immune checkpoint inhibitors (ICIs), 55 cancer patients undergoing chemotherapy (CT), and 53 non-cancer patients. Participants’ expectations about ICIs and CT were compared. Additional qualitative data were derived from semi-structured interviews.
Results
Among patients who did not receive ICIs, 63 (58%) had never heard of ICIs and 94 (87%) had large gaps in their knowledge of ICIs. Among ICI patients, 33 (62%) simply described ICIs without errors. ICI perception was positive, regardless of whether respondents received or had heard of ICIs, which became particularly evident when compared to CT. ICIs were rated as more promising, and all adverse effects were expected to be significantly lower than those of CT. Knowledge about ICIs was also limited in the interviewed ICI patients. Some patients reported adverse effects of ICIs that were mostly mild and well-tolerated or easily treated.
Conclusions
The lack of understanding of ICIs should be improved by activities to increase the knowledge of ICI patients and the general population. In contrast to CT, ICIs invoked fewer negative associations with efficacy and toxicity. Therefore, attention should be paid to risk awareness when educating patients. (Clinical trial registration number: DRKS00011868)
Trial Registration: German clinical trials register, www.germanctr.de, number DRKS00011868.